Coverage
Filings
| Filing | Date |
|---|---|
| Director/PDMR Shareholding | 17 Apr 2024 |
| FDA accepts GSK meningitis vaccine candidate file | 16 Apr 2024 |
| Amendment - Director/PDMR Shareholding | 16 Apr 2024 |
| Director/PDMR Shareholding | 15 Apr 2024 |
| Replacement - Total Voting Rights | 4 Apr 2024 |
| Director/PDMR Shareholding | 26 Mar 2024 |
| Notice of AGM | 25 Mar 2024 |
| Director/PDMR Shareholding | 22 Mar 2024 |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 22 Mar 2024 |
| New Phase III Jemperli data in endometrial cancer | 18 Mar 2024 |
| Director/PDMR Shareholding | 13 Mar 2024 |
| Board Committee Change | 8 Mar 2024 |